Amarantus Bioscience Holdings, Inc (AMBS)


Other OTC - Other OTC Delayed Price. Currency in USD
0.04-0.00 (-9.72%)
At close: 3:52 PM EDT
People also watch:
ELTPONCSMSTXIGXTNVIV
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Open0.05
Prev Close0.04
Bid0.00 x
Ask0.00 x
Day's Range0.04 - 0.05
52wk Range0.03 - 2.03
1y Target EstN/A
Market Cap2.94M
P/E Ratio (ttm)-0.01
Beta-0.53
Volume694,057
Avg Vol (3m)419,479
Dividend & YieldN/A (N/A)
Earnings DateN/A
Trade prices are not sourced from all markets
  • PR Newswire2 months ago

    Amarantus Announces Publication of Human Clinical Data for Engineered Skin Substitute in the Treatment of Life-Threatening Pediatric Severe Burns

    Amarantus BioScience Holdings, Inc. (AMBS), a biotechnology company focused on developing products for Regenerative Medicine, Neurology and Orphan Diseases, today announced the publication of a 16-subject clinical study of Engineered Skin Substitute ("ESS," or "Permaderm™") in children with life-threatening severe burns. In this study, ESS was compared with the standard of care (split-thickness autograft "AG") for treating full-thickness (dermal and epidermal layers of skin) life-threatening pediatric severe burns covering a total body surface area (TBSA) of 50% or greater. Amarantus' wholly-owned subsidiary Cutanogen Corporation is pursuing the development of ESS towards regulatory approval for the treatment of life-threatening severe burns.

  • PR Newswire4 months ago

    Amarantus Announces cGMP Manufacturing Readiness for Its Engineered Skin Substitute (ESS) Program at Lonza Walkersville

    Amarantus BioScience Holdings, Inc. (AMBS), a biotechnology company focused on developing products for Regenerative Medicine, Neurology and Orphan Diseases, today announced that the current Good Manufacturing Practices (cGMP) manufacturing process for its Engineered Skin Substitute (ESS) program is now qualified at Lonza Walkersville, Inc., a premier contract manufacturer providing cell and tissue-based products for clinical development. Reaching this milestone signifies that Amarantus is now positioned to supply ESS for its planned opening of the 10-patient, randomized, placebo-controlled, open-label Phase 2 clinical trial for the treatment of adult patients (ages 18-40 years old) with deep-partial and full-thickness thermal burns covering ≥50% of total body surface area (TBSA). The Company will open enrollment at the first site, the U.S. Army's Institute for Surgical Research (ISR) at Fort Sam Houston in Texas, under a Collaborative Research & Development Agreement (CRADA).

  • PR Newswire4 months ago

    Amarantus Completes Sale of Diagnostics Division, Announces Fiscal Year 2015 and First Quarter 2016 Financial Results

    Amarantus BioScience Holdings, Inc. (AMBS), a biotechnology company focused on developing products for Regenerative Medicine, Neurology and Orphan Diseases, today announced the closing of the sale of its wholly-owned subsidiary Amarantus Diagnostics, Inc. to Avant Diagnostics, Inc. (AVDX), and reported consolidated financial statements for fiscal year 2015, and for the first quarter of 2016. Amarantus' equity stake in Avant represents approximately 38% of the fully-diluted shares. "The sale of Amarantus Diagnostics to Avant was an important step for the Company as we continue to streamline our focus on our therapeutic portfolio," said Gerald E. Commissiong, President & CEO of Amarantus.